 M2 isoform pyruvate kinase emerging target antitumor therapy. letter, describe discovery 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones potent selective PKM2 activators found novel binding mode. original lead identified high throughput screening optimized efficient series via computer-aided structure-based drug design. representative compound series activator described literature used molecular tools probe biological effects PKM2 activation cancer cells. results suggested PKM2 activation alone sufficient alter cancer cell metabolism.